Fig. 1 · Structure

Documents & Downloads

Tofacitinib citrate (CP-690550)

Cat. No. A10241 CAS 540737-29-9

JAK3 inhibitor

CP-690550 (Tofacitinib citrate) is an orally available, highly selective inhibitor of the Janus kinase (JAK) family of enzymes.

In Stock

Publications for Tofacitinib citrate

1 publication citing this product

  1. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
JAK3 IC50 1nM
JAK2 IC50 20nM
JAK1 IC50 112nM
ROCK2 IC50 3.4μM
LCK IC50 3.87μM
IRK IC50 >10μM
CDK2 IC50 >10μM
CDK5 IC50 >10μM
EGFR IC50 >10μM
MAPK2/ERK2 IC50 >10μM
JNK1/SAPK1c IC50 >10μM
SAPK2a/p38 IC50 >10μM
SAPK2b/p38b2 IC50 >10μM
SAPK3/p38g IC50 >10μM
SAPK4/p38d IC50 >10μM
MAPKAPK2 IC50 >10μM
MAPKAP-K1b IC50 >10μM
MSK1 IC50 >10μM
PRAK IC50 >10μM
PKA IC50 >10μM
PKCα IC50 >10μM
PDK-1 IC50 >10μM
PKBα IC50 >10μM
SGK IC50 >10μM
p70S6K IC50 >10μM
GSK-3β IC50 >10μM
AMPK IC50 >10μM
Chk1 IC50 >10μM
CK2 IC50 >10μM
PHK IC50 >10μM
CSK IC50 >10μM
CDK2/CyclinA IC50 >10μM
PI3K IC50 >10μM

33 targets · Scroll to view more

Tofacitinib citrate (CP-690550) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Tofacitinib citrate (CP-690550) from 3 published references. In vitro models include ADSC adipocytes; PsAFLS. In vivo models include 8.5-week-old mice.

Tofacitinib citrate (CP-690550) In Vitro Studies

Tofacitinib-treated and R406-treated ADSC adipocytes showed increased basal lipolysis, but no significant increase in forskolin-stimulated lipolysis. Tofacitinib inhibited pSTAT3 and pSTAT1 expression in PsAFLS compared with vehicle control. In mouse adipose explants cultured in adipogenic medium, Tofacitinib increased UCP1 expression in subcutaneous explants, but not visceral explants, compared with DMSO. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Basal and stimulated lipolysis in adipocytes

Cell-based study · ADSC adipocytes [1]

Tofacitinib-treated and R406-treated ADSC adipocytes showed increased basal lipolysis, assessed by glycerol release, but no significant increase in forskolin-stimulated lipolysis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
quantification of glycerol releasebasal lipolysis ~2.5 fold increase of basal lipolysis[1]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM
Exposure duration
starved in DMEM containing 1% FBS for 1 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Tofacitinib

The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.

RESULTS > JAK-inactivated adipocytes acquire a brown-like metabolic program (S75); METHODS > Browning assay with tofacitinib, R406, JAK inhibitors and BMP7 (S151); METHODS > Lipolysis assay (S188); Figure 6 legend (S284, S285)

quantification of glycerol release: quantification of glycerol release; comparator: DMSO — RESULTS > JAK-inactivated adipocytes acquire a brown-like metabolic program (S75); Figure 6 legend (S284)

Tofacitinib inhibits pSTAT expression in PsAFLS

Cell-based study · PsAFLS (n=7) [2]

PsAFLS were treated with Tofacitinib and compared with vehicle control. Tofacitinib inhibited pSTAT3 and pSTAT1 expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Densitometry quantification of pSTAT3/pSTAT1Reported result Tofacitinib inhibited pSTAT3 and pSTAT1 expression in PsAFLS when compared with vehicle control[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
24 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tofacitinib

The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.

Results > Tofacitinib regulates STAT signalling in primary PsAFLS (S15); Figure 1 legend (S33, S34)

Densitometry quantification of pSTAT3/pSTAT1: Densitometry quantification of pSTAT3/pSTAT1; comparator: vehicle control — Results > Tofacitinib regulates STAT signalling in primary PsAFLS (S15); Figure 1 legend (S34)

Depot-specific UCP1 expression in adipose explants

Cell-based study · Subcutaneous and visceral adipose depots were dissected from 8 week old male C57/Bl6 mice (n=5) [1]

In adipose explants from male mice cultured in adipogenic medium, Tofacitinib increased UCP1 expression in subcutaneous explants, but not visceral explants, compared with DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
UCP1 expressionReported result up-regulation of UCP1 expression in explants of sub-cutaneous, but not visceral, origin[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 2 and 5 μM
Exposure duration
Media with fresh compound was replaced every other day. Following 7 days of treatments
Method
adipogenic medium containing DMSO, tofacitinib or R406
Co-treatment
Other interventions in this design: insulin 17 nM; dexamethasone 1 μM. Compound effect isolated by the comparison: DMSO, tofacitinib or R406.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Tofacitinib

The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.

RESULTS > Validation of tofacitinib and R406 browning compounds in primary adipocytes (S32); METHODS > Browning of mouse adipose tissue explants (S157, S160, S162, S163)

UCP1 expression: UCP1 expression; comparator: DMSO — RESULTS > Validation of tofacitinib and R406 browning compounds in primary adipocytes (S32)

Tofacitinib citrate (CP-690550) In Vivo Studies

Tofacitinib was applied to half of the back skin of mice, using DMSO as vehicle. Mice treated with ruxolitinib or Tofacitinib displayed skin darkening and hair growth, whereas no hair growth was evident in control-treated mice. [3]

Skin darkening and hair growth in mice

Animal study · 8.5-week-old mice [3]

~90% of 8.5-week-old mice treated with ruxolitinib or tofacitinib for 5 days displayed skin darkening and hair growth within 10 days of starting treatment, whereas no hair growth was evident in control-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
skin darkening and hair growthskin darkening and hair growth ~90%[3]

Conditions shared by the study groups

Route
half of the back skin
Treatment course
for 5 days
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tofacitinib 2 to 3%control-treated mice~90% of 8.5-week-old mice treated with ruxolitinib or tofacitinib for 5 days displayed skin darkening and hair growth within 10 days of starting treatment, whereas no hair growth was evident in control-treated mice (P < 0.0001 for ruxolitinib treatment and P = 0.04 for tofacitinib treatment)[3]
Tofacitinib 2 to 3%
Model: 8.5-week-old mice
Methods and source locations

Compound reported in the paper: Tofacitinib

The paper names Tofacitinib without stating the salt or form; not verified as the citrate form supplied as A10241. No dose conversion or lot validation.

RESULTS > Effects of JAK-STAT inhibition are dependent on the duration of telogen (S22); MATERIALS AND METHODS > Study design (S113); MATERIALS AND METHODS > Pharmacological inhibitors of JAK-STAT and other drugs used in this study (S140); Fig. 1 legend (S230)

skin darkening and hair growth: skin darkening and hair growth; comparator: control-treated mice — RESULTS > Effects of JAK-STAT inhibition are dependent on the duration of telogen (S22)

Tofacitinib 2 to 3% · RESULTS > Effects of JAK-STAT inhibition are dependent on the duration of telogen (S22); MATERIALS AND METHODS > Study design (S113); MATERIALS AND METHODS > Pharmacological inhibitors of JAK-STAT and other drugs used in this study (S140)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 540737-29-9
Applications JAK3 inhibitor
Formula C16H20N6O.C6H8O7
Molecular Weight 504.5
Synonyms CP-690550
SMILES
C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 94 mg/mL (186.32 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% methylcellulose

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tofacitinib citrate (CP-690550) Research References

  1. [1] Moisan A, Lee YK, Zhang JD, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol (2015). PMID: 25487280 DOI: 10.1038/ncb3075 Source material
  2. [2] Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis (2016). PMID: 26353790 DOI: 10.1136/annrheumdis-2014-207201 Source material
  3. [3] Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv (2015). PMID: 26601320 DOI: 10.1126/sciadv.1500973 Source material

Publications

1 publication citing this product

  1. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Added to your cart

View Cart Checkout
Loading...